This strategic investment unlocks new product offerings for Genovis to both existing and new customers and further paves the way for the expansion into new application areas, it states.

Following the investment, Genovis will own 25 percent of Sequrna. As part of the transaction, the parties have agreed to a call option with an end date on 30 June 2027, providing Genovis the right to acquire all shares of Sequrna under certain terms and conditions.

Genovis’ CEO, Fredrik Olsson, will join Sequrna’s Board of Directors.

“We are excited to partner with SEQURNA and the very talented team lead by Björn Reinius. We have been following Sequrna for a while and are impressed with its unique RNase inhibitor technology, which provide customers with improved workflows, simplified storage and logistics, at a competitive price for the end user. The investment in Sequrna supports our long-term strategy to expand our portfolio by inorganic growth initiatives and continue to bring unique products to our customers within the life science industry,” says Olsson.

RNase inhibitors

Genovis will utilize its distribution network to market and sell Sequrna’s RNase inhibitors alongside its own catalogue of tools for the biopharmaceutical and research industries.

Sequrna has developed synthetic, thermostable RNase inhibitors which solve many of the shortcomings of conventional protein-based RNase inhibitors, such as stability and integrity, batch-to-batch variability and interference with downstream applications.

“My Co-founders and I are very pleased to onboard Genovis as a strategic partner. Since the launch of our first RNase inhibitor, things have been moving quickly and we see a strong demand for our product. We look forward to receiving the benefit of Genovis’ distribution platform and expertise in the industry, which will benefit SEQURNA’s growth and business development going forward,” says CEO and Co-founder of Sequrna, Björn Reinius.

The full terms of the transactions are not disclosed.

Photo: iStock